Enzo approved to begin phase 2 study in Israel of EGS21 for treatment of fatty liver disease

By Lisa Kerner

Charlotte, N.C., July 17 - Enzo Biochem, Inc. said it received regulatory approval from the Helsinki Committee of Hebrew University-Hadassah Medical Center in Jerusalem, Israel, to begin a phase 2 randomized, double-blind clinical trial of EGS21 for the treatment of non-alcoholic steatohepatitis or fatty liver disease

The study is being funded in part by a $1.0 million grant from the Israel-U.S. Binational Industrial Research and Development Foundation.

Preclinical studies, a phase 1 safety trial and a pilot open label clinical trail showed positive trends towards a possible therapeutic effect of EGS21.

EGS21 was shown to alleviate the symptoms of non-alcoholic steatohepatitis and its associated metabolic syndrome in animal models.

Approximately 8.6 million obese adult Americans may have non-alcoholic steatohepatitis, with another 30.1 million affected by the milder form of fatty liver.

The disease usually occurs together with obesity, type II diabetes and hyperlipidemia.

Based in Farmingdale, N.Y., Enzo researches, develops and manufactures health care products based on molecular biology and genetic engineering techniques.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.